Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for Annals of Oncology

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 917-918

  Swanton, C ^a,b   Andre F ^c   Mardis, E ^d  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENETICS; HUMAN; MALE; MELANOMA; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84919445438     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu060     Document Type: Editorial

References (11)

1. Davies, H., Bignell, G.R., Cox, C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
2. Chapman, P.B., Hauschild, A., Robert, C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
3. Fisher, R., Pusztai, L., Swanton, C., Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108 (2013), 479–485.
4. Jang, S., Atkins, M.B., Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol 14 (2013), e60–e69.
5. Van Allen, E.M., Wagle, N., Sucker, A., et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4 (2014), 94–109.
6. Whittaker, S.R., Theurillat, J.P., Van Allen, E., et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 3 (2013), 350–362.
7. Shi, H., Hugo, W., Kong, X., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4 (2014), 80–93.
8. Romano, E., Pradervand, S., Paillusson, A., et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res 19 (2013), 5749–5757.
9. Turajlic, S., Furney, S.J., Stamp, G., et al. Whole genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol 25 (2014), 959–967.
10. Diaz, L.A. Jr, Williams, R.T., Wu, J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486 (2012), 537–540.
11. Su, K.Y., Chen, H.Y., Li, K.C., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30 (2012), 433–440.